These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 20630573

  • 1. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
    Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T.
    Urology; 2010 Sep; 76(3):764.e7-13. PubMed ID: 20630573
    [Abstract] [Full Text] [Related]

  • 2. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A, Asano T, Ito K, Sumitomo M, Asano T.
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [Abstract] [Full Text] [Related]

  • 3. Ritonavir interacts with bortezomib to enhance protein ubiquitination and histone acetylation synergistically in renal cancer cells.
    Sato A, Asano T, Ito K, Asano T.
    Urology; 2012 Apr; 79(4):966.e13-21. PubMed ID: 22296623
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
    Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M.
    J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283
    [Abstract] [Full Text] [Related]

  • 7. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, Konda BM, Black KL, Koeffler HP.
    Clin Cancer Res; 2007 Feb 01; 13(3):1045-52. PubMed ID: 17289901
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM.
    Cancer Res; 2001 Dec 01; 61(23):8492-7. PubMed ID: 11731433
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
    Dietrich CS, Greenberg VL, DeSimone CP, Modesitt SC, van Nagell JR, Craven R, Zimmer SG.
    Gynecol Oncol; 2010 Jan 01; 116(1):126-30. PubMed ID: 19875160
    [Abstract] [Full Text] [Related]

  • 13. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM.
    Cancer Res; 2000 Sep 15; 60(18):5165-70. PubMed ID: 11016644
    [Abstract] [Full Text] [Related]

  • 14. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A, Asano T, Ito K, Asano T.
    Int J Oncol; 2012 Jul 15; 41(1):46-52. PubMed ID: 22470109
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR, Zimmer SG, Modesitt SC.
    Gynecol Oncol; 2007 Mar 15; 104(3):596-601. PubMed ID: 17049973
    [Abstract] [Full Text] [Related]

  • 16. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
    Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF.
    BMC Cancer; 2006 Jul 11; 6():183. PubMed ID: 16834771
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
    Dalgard CL, Van Quill KR, O'Brien JM.
    Clin Cancer Res; 2008 May 15; 14(10):3113-23. PubMed ID: 18483379
    [Abstract] [Full Text] [Related]

  • 18. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
    Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades N.
    Clin Cancer Res; 2005 May 15; 11(10):3958-65. PubMed ID: 15897598
    [Abstract] [Full Text] [Related]

  • 19. Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells.
    Seo SK, Jin HO, Lee HC, Woo SH, Kim ES, Yoo DH, Lee SJ, An S, Rhee CH, Hong SI, Choe TB, Park IC.
    Mol Pharmacol; 2008 Mar 15; 73(3):1005-12. PubMed ID: 18156316
    [Abstract] [Full Text] [Related]

  • 20. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP.
    Oncol Rep; 2006 Jan 15; 15(1):187-91. PubMed ID: 16328054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.